Apretude (cabotegravir) is a prescription drug used to help prevent HIV. It comes as a liquid suspension that a healthcare professional injects into your muscle. Apretude is a long-acting drug that’s ...

Apretude is a long-acting injectable medication used to prevent HIV (human immunodeficiency virus) infection in adults and some children who are at high risk of contracting the virus. Apretude is ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

A new injectable treatment for HIV pre-exposure prevention, or PrEP, has been approved by the Federal Drug Administration. The drug, Apretude, is approved for at-risk adults and adolescents who weigh ...

GlaxoSmithKline' majority-owned HIV unit ViiV has scored a key FDA approval, getting approval for its long-acting drug cabotegravir as the first injectable for pre-exposure prophylaxis (PrEP) ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

As GSK’s ViiV Healthcare looks to widen the reach of its HIV franchise, Médecins Sans Frontières (MSF) has been working to secure access to the company's long-acting HIV prevention drug, Apretude, for ...

A decade into the era of the HIV prevention pill, called PrEP, efforts to leverage its heralded power to curb new infections have stagnated in the United States. This shortfall is a key reason the ...

MONTRÉAL, March 25, 2025 /CNW/ - ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (GSK), with Pfizer Inc. and Shionogi as shareholders, is pleased to announce ...

The Food and Drug Administration has approved the first long-acting injectable medication for use as pre-exposure prevention, or PrEP, against HIV, the agency announced Monday. Apretude, the new drug, ...